{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:35:37Z","timestamp":1788212137429,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.antiviral.2014.05.003","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T23:31:48Z","timestamp":1399678308000},"page":"95-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Antiviral activity of topoisomerase II catalytic inhibitors against Epstein\u2013Barr virus"],"prefix":"10.1016","volume":"107","author":[{"given":"Ting","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.antiviral.2014.05.003_b0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jcv.2011.05.023","article-title":"B-cell polyclonal activation and Epstein\u2013Barr viral abortive lytic cycle are two key features in acute infectious mononucleosis","volume":"52","author":"Al Tabaa","year":"2011","journal-title":"J. Clin. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2014.05.003_b0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14728214.2011.591786","article-title":"Emerging drugs for varicella-zoster virus infections","volume":"16","author":"Andrei","year":"2011","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"5","key":"10.1016\/j.antiviral.2014.05.003_b0015","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/JVI.06620-11","article-title":"In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype\u2013genotype associations and highlight differences between antiherpesvirus drugs","volume":"86","author":"Andrei","year":"2012","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2014.05.003_b0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.7326\/0003-4819-80-2-249","article-title":"Adriamycin. A new anticancer drug with significant clinical activity","volume":"80","author":"Blum","year":"1974","journal-title":"Ann. Intern. Med."},{"issue":"7","key":"10.1016\/j.antiviral.2014.05.003_b0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein\u2013Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.antiviral.2014.05.003_b0030","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1073\/pnas.82.12.4085","article-title":"Activation of expression of latent Epstein\u2013Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA","volume":"82","author":"Countryman","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"12","key":"10.1016\/j.antiviral.2014.05.003_b0035","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.4049\/jimmunol.144.12.4788","article-title":"Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt\u2019s lymphoma cell line Akata","volume":"144","author":"Daibata","year":"1990","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.antiviral.2014.05.003_b0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<71::AID-IJC11>3.0.CO;2-1","article-title":"Antibodies to the Epstein\u2013Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma","volume":"86","author":"Dardari","year":"2000","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.antiviral.2014.05.003_b0045","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1128\/JVI.64.9.4059-4066.1990","article-title":"Topoisomerase II cleavage of herpes simplex virus type 1 DNA in vivo is replication dependent","volume":"64","author":"Ebert","year":"1990","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2014.05.003_b0050","first-page":"510","article-title":"A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity","volume":"51","author":"Eder","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2014.05.003_b0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/bmb\/ldt011","article-title":"Recent developments in anti-herpesvirus drugs","volume":"106","author":"Field","year":"2013","journal-title":"Br. Med. Bull."},{"issue":"2","key":"10.1016\/j.antiviral.2014.05.003_b0060","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/jac\/dki240","article-title":"Epstein\u2013Barr virus infections: prospects for treatment","volume":"56","author":"Gershburg","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.antiviral.2014.05.003_b0065","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1368-7646(02)00021-3","article-title":"Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms","volume":"5","author":"Gilbert","year":"2002","journal-title":"Drug Resist. Updat."},{"issue":"2","key":"10.1016\/j.antiviral.2014.05.003_b0070","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1128\/AAC.05274-11","article-title":"Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi\u2019s sarcoma-associated herpesvirus","volume":"56","author":"Gonzalez-Molleda","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.antiviral.2014.05.003_b0075","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.4049\/jimmunol.174.11.6599","article-title":"EBV and systemic lupus erythematosus: a new perspective","volume":"174","author":"Gross","year":"2005","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.antiviral.2014.05.003_b0080","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.3390\/molecules15075031","article-title":"Selecting diversified compounds to build a tangible library for biological and biochemical assays","volume":"15","author":"Gu","year":"2010","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.antiviral.2014.05.003_b0085","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/JVI.01999-06","article-title":"Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein\u2013Barr virus replication","volume":"81","author":"Guerreiro-Cacais","year":"2007","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.antiviral.2014.05.003_b0090","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1128\/JVI.70.7.4523-4529.1996","article-title":"Inhibition of topoisomerase II by ICRF-193 prevents efficient replication of herpes simplex virus type 1","volume":"70","author":"Hammarsten","year":"1996","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2014.05.003_b0095","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0092-8674(88)90028-1","article-title":"Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein\u2013Barr virus","volume":"55","author":"Hammerschmidt","year":"1988","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.antiviral.2014.05.003_b0100","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1128\/JVI.1.5.1045-1051.1967","article-title":"Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line","volume":"1","author":"Hinuma","year":"1967","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2014.05.003_b0105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0022-2836(67)90307-5","article-title":"Selective extraction of polyoma DNA from infected mouse cell cultures","volume":"26","author":"Hirt","year":"1967","journal-title":"J. Mol. Biol."},{"issue":"22","key":"10.1016\/j.antiviral.2014.05.003_b0110","doi-asserted-by":"crossref","first-page":"13984","DOI":"10.1128\/JVI.79.22.13984-13992.2005","article-title":"Epstein\u2013Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines","volume":"79","author":"Hong","year":"2005","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2014.05.003_b0115","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1182\/blood-2003-06-2171","article-title":"Chronic active Epstein\u2013Barr virus infection associated with mutations in perforin that impair its maturation","volume":"103","author":"Katano","year":"2004","journal-title":"Blood"},{"issue":"Pt 10","key":"10.1016\/j.antiviral.2014.05.003_b0120","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1099\/0022-1317-74-10-2263","article-title":"Topoisomerase I and II activities are required for Epstein\u2013Barr virus replication","volume":"74","author":"Kawanishi","year":"1993","journal-title":"J. Gen. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2014.05.003_b0125","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/14653240310002243","article-title":"Suppression of EBV release from irradiated B lymphoblastoid cell-lines: superior activity of ganciclovir compared with acyclovir","volume":"5","author":"Keever-Taylor","year":"2003","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.antiviral.2014.05.003_b0130","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.1995.13.5.1136","article-title":"Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer","volume":"13","author":"Kennedy","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2014.05.003_b0135","series-title":"Fields Virology","first-page":"2603","article-title":"Epstein\u2013Barr virus and its replication","author":"Kieff","year":"2007"},{"key":"10.1016\/j.antiviral.2014.05.003_b0140","doi-asserted-by":"crossref","unstructured":"Kimberlin, D.W., Whitley, R.J., 2007. Antiviral therapy of HSV-1 and -2.","DOI":"10.1017\/CBO9780511545313.065"},{"issue":"2","key":"10.1016\/j.antiviral.2014.05.003_b0145","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood.V98.2.280","article-title":"Clinical and virologic characteristics of chronic active Epstein\u2013Barr virus infection","volume":"98","author":"Kimura","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.antiviral.2014.05.003_b0150","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1086\/367988","article-title":"Prognostic factors for chronic active Epstein\u2013Barr virus infection","volume":"187","author":"Kimura","year":"2003","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.antiviral.2014.05.003_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archinte.1956.00250250007001","article-title":"Clinical and laboratory studies of novobiocin, a new antibiotic","volume":"98","author":"Kirby","year":"1956","journal-title":"AMA Arch. Intern. Med."},{"key":"10.1016\/j.antiviral.2014.05.003_b0160","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.10.011","article-title":"Resistance of human cytomegalovirus to ganciclovir\/valganciclovir: a comprehensive review of putative resistance pathways","volume":"101","author":"Komatsu","year":"2014","journal-title":"Antiviral Res."},{"issue":"2","key":"10.1016\/j.antiviral.2014.05.003_b0165","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1006\/viro.1993.1397","article-title":"Epstein\u2013Barr virus gene expression in oral hairy leukoplakia","volume":"195","author":"Lau","year":"1993","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.antiviral.2014.05.003_b0170","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1128\/JVI.01512-10","article-title":"A new model of Epstein\u2013Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas","volume":"85","author":"Ma","year":"2011","journal-title":"J. Virol."},{"issue":"18","key":"10.1016\/j.antiviral.2014.05.003_b0175","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2174\/0929867043364531","article-title":"Etoposide: discovery and medicinal chemistry","volume":"11","author":"Meresse","year":"2004","journal-title":"Curr. Med. Chem."},{"issue":"24","key":"10.1016\/j.antiviral.2014.05.003_b0185","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1073\/pnas.85.24.9801","article-title":"Genome rearrangements activate the Epstein\u2013Barr virus gene whose product disrupts latency","volume":"85","author":"Rooney","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.antiviral.2014.05.003_b0190","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1128\/JVI.01319-07","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus ori-Lyt-dependent DNA replication: involvement of host cellular factors","volume":"82","author":"Wang","year":"2008","journal-title":"J. Virol."},{"issue":"16","key":"10.1016\/j.antiviral.2014.05.003_b0195","doi-asserted-by":"crossref","first-page":"8090","DOI":"10.1128\/JVI.02379-08","article-title":"Topoisomerase I and RecQL1 function in Epstein\u2013Barr virus lytic reactivation","volume":"83","author":"Wang","year":"2009","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.antiviral.2014.05.003_b0200","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/AAC.47.7.2186-2192.2003","article-title":"In vitro activities of benzimidazole d- and l-ribonucleosides against herpesviruses","volume":"47","author":"Williams","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.antiviral.2014.05.003_b0205","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1128\/AAC.01259-13","article-title":"Antiviral activity of (+)-rutamarin against Kaposi\u2019s sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II","volume":"58","author":"Xu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2014.05.003_b0210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF01310708","article-title":"Role of DNA topoisomerase I in the replication of herpes simplex virus type 2","volume":"110","author":"Yamada","year":"1990","journal-title":"Arch. Virol."},{"issue":"10","key":"10.1016\/j.antiviral.2014.05.003_b0215","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein\u2013Barr virus: 40years on","volume":"4","author":"Young","year":"2004","journal-title":"Nat. Rev. Cancer"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214001326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214001326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T21:10:11Z","timestamp":1689196211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214001326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":42,"alternative-id":["S0166354214001326"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.05.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral activity of topoisomerase II catalytic inhibitors against Epstein\u2013Barr virus","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}